Suggested Remit: To appraise the clinical and cost effectiveness of elotuzumab in combination with pomalidomide and low-dose dexamethasone within its marketing authorisation for treating relapsed and refractory multiple myeloma.
Status Suspended
Decision Selected
Process STA 2018
ID number 1467

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
28 September 2018 Suspended. Suspended
28 August 2018 - 25 September 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
18 September 2018 The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of elotuzumab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma ID1467. We have recently invited stakeholders to respond to a written consultation on the draft scope. The company that is developing elotuzumab have shared confidential information with NICE. In light of this information the Institute will not be progressing with the scoping exercise. Consequently the consultation on the draft scope will be closed early. The topic will still progress to Technology Appraisal stage If you have any comments or concerns please contact the project manager for this appraisal Michelle Adhemar at
13 February 2018 Referral
13 February 2018 In progress. Topic referred

For further information on our processes and methods, please see our CHTE processes and methods manual